Bernard Gilly, Gensight CEO (Eric Piermont/AFP via Getty Images)
December 15, 2020 02:13 PM ESTUpdated February 11, 03:20 PM
Discovery
In Focus

They thought their gene ther­a­py failed. In­stead, it spawned a med­ical mys­tery

Jason Mast

Editor

José-Alain Sa­hel was on a rare va­ca­tion in Por­tu­gal in the spring of 2018 when his phone rang with grim news: The gene ther­a­py he …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

Three drug­mak­ers sue US over 340B dis­counts to STD clin­ics they al­lege don’t qual­i­fy

Ver­tex gets 'van­za triple' ap­proval and Trikaf­ta ex­pan­sion — with boxed warn­ings

A service from the Financial Times